RACGP examiner reports · fix it Missing the detail in the stem Skipping the age, medicine, allergy or setting that changes the answer.
What it looks like: One line in the stem (a current medicine, pregnancy, kidney function, an allergy, a rural setting) makes the usual answer wrong. Reading for the diagnosis and skimming the rest misses it.
How to fix it: Before answering, list the patient's medicines, conditions and setting from the stem. For each option you like, check it against that list for interactions and contraindications.
The drill: 15 questions Questions from the General practice bank picked because they test this habit. You answer one at a time and see the explanation straight away.
The first 3 are free, below and in the drill with a free account. Any General practice plan opens all 15.
Try 3 now. No account needed. Question 1 of 3 Women's, sexual and reproductive health
A 20-year-old woman with a body mass index of 36 kg/m2 has hirsutism, acne and heavy, infrequent periods, and investigations confirm polycystic ovary syndrome. She is not trying to conceive and has no contraindication to any treatment. Which is the most appropriate first-line treatment for the underlying condition? A Combined oral contraceptive pill B Metformin C Letrozole D Lifestyle change for weight loss E Levonorgestrel intrauterine device
Pick an answer to see the explanation. Next question →
Question 1 of 3 · Women's, sexual and reproductive health
A 20-year-old woman with a body mass index of 36 kg/m2 has hirsutism, acne and heavy, infrequent periods, and investigations confirm polycystic ovary syndrome. She is not trying to conceive and has no contraindication to any treatment. Which is the most appropriate first-line treatment for the underlying condition?
Combined oral contraceptive pill Metformin Letrozole Lifestyle change for weight loss Levonorgestrel intrauterine device Show the answer D. Lifestyle change for weight loss
In polycystic ovary syndrome with excess weight, the underlying drivers are insulin resistance and hyperandrogenism, both worsened by obesity. The international guideline recommends healthy lifestyle behaviours, combining diet and physical activity, for all women with PCOS, and modest weight loss of 5 to 10% can restore ovulation and improve hyperandrogenism and metabolic risk. Lifestyle change is therefore first-line management of the underlying condition. The combined oral contraceptive pill is the first-line pharmacological treatment for hirsutism and irregular cycles, and provides endometrial protection, but treats manifestations rather than the metabolic drivers. Metformin is added mainly for metabolic features or weight, particularly when lifestyle measures are insufficient. Letrozole is first-line ovulation induction for women trying to conceive, which she is not. References: Teede HJ et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2023.
Source: International Evidence-based Guideline for the Assessment and Management of PCOS (International PCOS Network (Monash University)), checked Nov 2026
Why not A: First-line drug for hirsutism and cycle control, but it treats manifestations rather than the underlying drivers. Why not B: Added mainly for metabolic features when lifestyle measures are insufficient. Why not C: Used for ovulation induction in women trying to conceive. Why not E: Gives endometrial protection and cycle control but does not address the underlying condition. Question 2 of 3 · Musculoskeletal health
A 52-year-old woman has newly diagnosed seropositive rheumatoid arthritis with high disease activity affecting her hands, wrists and feet. Her renal and liver function and chest X-ray are normal, she drinks alcohol rarely, has no lung disease and is not planning a pregnancy. Which conventional synthetic disease-modifying drug should be the anchor of her initial therapy?
Hydroxychloroquine Sulfasalazine Methotrexate Leflunomide Adalimumab Show the answer C. Methotrexate
Methotrexate is the anchor drug for newly diagnosed rheumatoid arthritis and should be part of the first treatment strategy unless contraindicated, usually as weekly oral or subcutaneous dosing with folic acid, often with short-term low-dose glucocorticoid bridging. It has the strongest evidence for controlling disease activity and slowing radiographic progression, and it combines well with other conventional and biological agents. Hydroxychloroquine and sulfasalazine are commonly added in combination (triple therapy) or used for milder disease, but as monotherapy they are less effective for high disease activity. Leflunomide is the usual alternative when methotrexate is contraindicated or not tolerated. Failure of conventional synthetic therapy is required before PBS-subsidised biological or targeted synthetic agents. References: Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18; Therapeutic Guidelines Limited. Rheumatoid arthritis. In: Therapeutic Guidelines: Rheumatology. Melbourne.
Why not A: Hydroxychloroquine is used in combination or for mild disease, not as the anchor for high activity. Why not B: Sulfasalazine is a combination partner or alternative rather than the preferred anchor. Why not D: Leflunomide is the usual alternative when methotrexate cannot be used. Why not E: Biological agents follow an adequate trial of conventional synthetic DMARDs under PBS criteria. Question 3 of 3 · Older persons' health
An 87-year-old woman in residential aged care has severe osteoarthritic knee pain disrupting her sleep despite regular paracetamol, topical diclofenac and physiotherapy. She has never taken opioids, takes sertraline, and her eGFR is 28 mL/min/1.73 m2. She often refuses tablets. After discussion, she and her family agree to a trial of an opioid. Which is most appropriate?
Buprenorphine 5 microgram/hour weekly patch Fentanyl 12 microgram/hour three-day patch Tramadol sustained-release 50 mg twice daily Morphine oral liquid 2.5 mg four times daily Codeine 30 mg with paracetamol four times daily Show the answer A. Buprenorphine 5 microgram/hour weekly patch
If an opioid trial is agreed for severe chronic pain in a frail older person, a low-dose transdermal buprenorphine patch is a reasonable choice: it can be started in opioid-naive people at 5 microgram/hour, is changed weekly, does not need dose adjustment in renal impairment and avoids tablets. Fentanyl patches are contraindicated in opioid-naive patients. The trial should have clear functional goals, monitoring for sedation, constipation and falls, regular laxatives and a planned review within a few weeks, stopping it if it does not help. Non-drug measures should continue.
Why not B: Fentanyl patches are only for opioid-tolerant people, and starting one in an opioid-naive woman risks respiratory depression. Why not C: Tramadol adds serotonin toxicity risk with sertraline, lowers the seizure threshold and is a tablet she may refuse. Why not D: Morphine's active metabolites accumulate when the eGFR is below 30, causing sedation and confusion. Why not E: Codeine's effect depends on variable CYP2D6 metabolism, it accumulates in renal impairment and it is a tablet she may refuse. Create a free account to save your results and keep going →
Where the RACGP examiners flagged it All RACGP examiner reports →
Fellowship Ready is not affiliated with or endorsed by the RACGP. Not affiliated with the RACGP.